Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent B-Cell Non-Hodgkin's Lymphomas”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00406809
What this trial is testing

ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

Who this might be right for
Chronic Lymphoid LeukemiaLymphoid MalignanciesNon-Hodgkin's Lymphoma+3 more
AbbVie (prior sponsor, Abbott) 81
Early research (Phase 1)Looking for participantsNCT04223765
What this trial is testing

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Who this might be right for
Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more
UNC Lineberger Comprehensive Cancer Center 20
Testing effectiveness (Phase 2)Study completedNCT00764517
What this trial is testing

Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma

Who this might be right for
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRecurrent Indolent Adult Non-Hodgkin Lymphoma+1 more
OHSU Knight Cancer Institute 57
Testing effectiveness (Phase 2)Study completedNCT00612183
What this trial is testing

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Who this might be right for
Non-Hodgkin's LymphomaMantle Cell Lymphoma
SymBio Pharmaceuticals 56
Testing effectiveness (Phase 2)Looking for participantsNCT04110301
What this trial is testing

MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)

Who this might be right for
Follicular Lymphoma and Marginal Zone Lymphoma
Beijing Mabworks Biotech Co., Ltd. 53
Testing effectiveness (Phase 2)Looking for participantsNCT06386315
What this trial is testing

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

Who this might be right for
Indolent B-Cell Non-Hodgkin LymphomaRecurrent Indolent B-Cell Non-Hodgkin LymphomaRefractory Indolent B-Cell Non-Hodgkin Lymphoma+2 more
Mayo Clinic 112
Testing effectiveness (Phase 2)Study completedNCT04703686
What this trial is testing

Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma RefractoryRefractory Indolent Adult Non-Hodgkin LymphomaRefractory Transformed B-cell Non-Hodgkin Lymphoma+2 more
The Lymphoma Academic Research Organisation 67
Testing effectiveness (Phase 2)Looking for participantsNCT07365306
What this trial is testing

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent High Grade B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Primary Mediastinal Large B-Cell Lymphoma+5 more
City of Hope Medical Center
Testing effectiveness (Phase 2)Looking for participantsNCT06238648
What this trial is testing

Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedPrimary Mediastinal Large B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Academic and Community Cancer Research United 120
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Early research (Phase 1)Study completedNCT03985189
What this trial is testing

Study of ME-401 in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

Who this might be right for
Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma
Kyowa Kirin Co., Ltd. 14
Early research (Phase 1)Looking for participantsNCT06015880
What this trial is testing

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 30
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Looking for participantsNCT04669171
What this trial is testing

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone Lymphoma
Enterome 80
Testing effectiveness (Phase 2)Ended earlyNCT05265975
What this trial is testing

ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

Who this might be right for
Diffuse Large B-cell LymphomaIndolent Non-Hodgkin Lymphoma
Antengene Corporation 54
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Testing effectiveness (Phase 2)Looking for participantsNCT06784726
What this trial is testing

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

Who this might be right for
Recurrent Diffuse Large B-Cell LymphomaRecurrent Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedRecurrent Grade 3b Follicular Lymphoma+9 more
University of Washington 27
Early research (Phase 1)Not Yet RecruitingNCT07638982
What this trial is testing

Axatilimab + CAR-T for High-Risk Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma (HGBCL)+3 more
Northside Hospital, Inc. 29
Testing effectiveness (Phase 2)Study completedNCT01282424
What this trial is testing

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

Who this might be right for
Follicular LymphomaSmall Lymphocytic LymphomaLymphoplasmacytic Lymphoma+1 more
Gilead Sciences 125
Testing effectiveness (Phase 2)WithdrawnNCT00837174
What this trial is testing

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Who this might be right for
Non-Hodgkin Lymphoma
The Methodist Hospital Research Institute
Next Page
43